---
layout: post
title: "Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Alternative Form of Hearing"
date: 2026-02-05 18:56:35 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2023-18241
original_published: 2023-08-24 00:00:00 +0000
significance: 8.00
---

# Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Alternative Form of Hearing

**Published:** February 05, 2026 18:56 UTC
**Source:** Federal Register
**Original Published:** August 24, 2023 00:00 UTC
**Document Number:** 2023-18241

## Summary

The Food and Drug Administration (FDA) announces an alternative form of hearing regarding the Center for Drug Evaluation and Research's (CDER's) proposal to refuse to approve ITCA 650 (exenatide in DUROS device), a drug-device combination product that is the subject of a new drug application (NDA) submitted by Intarcia Therapeutics, Inc. (Intarcia). CDER is holding a public hearing before an advisory committee under FDA regulations as an alternative form of hearing.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2023/08/24/2023-18241/endocrinologic-and-metabolic-drugs-advisory-committee-notice-of-alternative-form-of-hearing)
- API: https://www.federalregister.gov/api/v1/documents/2023-18241

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
